Cargando…
An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
Hardy and Mummery discuss the recent positive findings in the clinical trial of lecanemab in early Alzheimer’s disease, and the implications for the amyloid hypothesis. They argue that the results mark a turning point for the Alzheimer’s field, but that taking anti-amyloid therapies into clinical pr...
Autores principales: | Hardy, John, Mummery, Catherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115350/ https://www.ncbi.nlm.nih.gov/pubmed/36797987 http://dx.doi.org/10.1093/brain/awad049 |
Ejemplares similares
-
Candesartan—the next anti-amyloid drug?
por: Yasar, Sevil
Publicado: (2022) -
The arthritis connection to inflammatory bowel disease (IBD): why has it taken so long to understand it?
por: Ashrafi, Maedeh, et al.
Publicado: (2021) -
In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer’s disease
por: Toombs, Jamie, et al.
Publicado: (2020) -
Taking patient reported outcomes centre stage in cancer research – why has it taken so long?
por: Selby, Peter, et al.
Publicado: (2018) -
Another step of the APXPS evolution taken at MAX IV synchrotron
por: Nemšák, Slavomir
Publicado: (2021)